Related by context. All words. (Click for frequent words.) 87 p = #.# [002] 80 p = 78 P = .# 74 placebo p = 71 % CI #.#-#.# [002] 70 confidence interval CI 70 placebo p 68 median PFS 67 n = 67 % CI #.#-#.# [006] 66 % CI #.#-#.# [003] 66 ≥ 65 CI #.#-#.# [002] 65 Secondary endpoints included 65 p = .# [002] 65 CI = 65 placebo 65 MADRS score 64 p = NS 64 CI -#.# 64 mg QD 63 statistically significant p 63 oxycodone CR 63 mcg QD 63 lopinavir r arm 63 % CI #.#-#.# [007] 63 progression TTP 63 Median PFS 63 biochemical recurrence 62 confidence interval #.#-#.# 62 Secondary endpoints include 62 % Confidence Interval 62 Secondary endpoints 62 FOLFIRI alone 61 -#.# ± [002] 61 #mg/day [001] 61 LVEF 61 % CI #.#-#.# [008] 61 univariate analysis 61 posttreatment 61 pg mL 61 MACCE 61 Median progression 61 IU mL 61 secondary endpoint 61 mcg kg 61 -#.# mg dL [002] 61 -#.# mg dL [001] 61 p = #.# [003] 61 lumbar spine BMD 61 plus methotrexate 60 IPSS 60 lispro 60 target vessel revascularization 60 chlorambucil 60 achieved ACR# 60 comparator arm 60 biochemical relapse 60 ± 60 binary restenosis 60 statistically significant p = 60 adjunctive placebo 60 #mg BID [001] 60 mg d 60 5-FU/LV 60 postoperatively 60 pg ml 60 atazanavir ritonavir 60 Hazard Ratio HR 60 clodronate 60 RGT arm 60 CR nPR 60 plus dexamethasone 60 copies mL 59 sd = 59 interquartile range 59 CR CRu 59 lopinavir r 59 nonfatal MI 59 #mg BID [003] 59 free survival PFS 59 GERD symptom 59 achieved statistical significance 59 placebo fluoxetine 59 mg BID 59 μmol L 59 mitoxantrone 59 RLAI 59 mg kg dose 59 discontinuations due 59 ng dL 59 postop 59 ipsilateral stroke 59 creatinine ratio 59 #.#/#.# mmHg [001] 59 Pred Forte 59 4mg/kg 59 hip BMD 59 nonsignificant 59 FOLFOX4 58 pegylated interferon alfa 2b 58 methotrexate monotherapy 58 #mg QD [001] 58 HbA 1c levels 58 p = .# [001] 58 TAXUS p value 58 demonstrated statistically significant 58 tolterodine ER 58 CI #.#-#.# [001] 58 HbA1c levels 58 preoperative PSA 58 plus MTX 58 Target Lesion Revascularization TLR 58 postintervention 58 reinfarction 58 Rating Scale MADRS 58 statistically significant improvement 58 plus gemcitabine 58 HBeAg seroconversion 58 LEXIVA r 58 DAS# [002] 58 dyspnea 58 diameter stenosis 58 MADRS 58 = #.#-#.# 58 virologic response 58 mg TID 58 #mg QD [002] 58 % CI #.#-#.# [001] 58 febrile neutropenia 58 periprocedural 58 ischemia driven 58 mg Lucentis 58 mg ustekinumab 58 statistically significant reduction 58 x ULN 58 mL kg 58 composite endpoint 58 placebo dexamethasone 58 #.#mg/dL 58 leukopenia 58 stent binary restenosis 58 FOLFOX 58 PANSS scores 57 WOMAC pain 57 Flu Cy 57 Elitek 57 PREZISTA ritonavir 57 preintervention 57 HCV RNA 57 Free Survival PFS 57 timepoints 57 mcg BID 57 mg kg 57 ropivacaine 57 HDRS 57 evaluable 57 ‰ ¥ 57 p ≤ 57 desvenlafaxine succinate 57 HBeAg negative patients 57 P ≤ 57 Kaplan Meier analysis 57 nonfatal myocardial infarction 57 CIMZIA TM 57 urate lowering therapy 57 refractory ischemia 57 Median survival 57 tamsulosin 57 tiotropium 57 FOLFOX4 alone 57 lowest tertile 57 tirofiban 57 peginterferon alfa 2a 57 #mg/kg [002] 57 CI #.#-#.# p = 57 QTcF 57 postoperative 57 highest tertile 57 cerebrovascular events 57 tumor progression TTP 57 CDAI 57 systolic BP 57 inflammatory lesions 57 NMIBC 57 severe neutropenia 57 timepoint 57 HIV RNA 57 ADAS cog 57 XIENCE V PROMUS Stent 57 SGRQ 57 Montgomery Åsberg Depression 57 YMRS 56 serum HCV RNA 56 laboratory abnormalities 56 TAXUS Express Stent 56 severe hypoglycemic 56 peripheral edema 56 ug dose 56 Postoperative 56 mg dL 56 primary endpoint 56 locoregional disease 56 certolizumab 56 mm Hg 56 ± SD 56 LPV r 56 preoperative 56 μg mL 56 International Prostate Symptom 56 AUC0 56 EBRT 56 Hazard Ratio = 56 target lesion revascularization 56 normotensive 56 nasopharyngitis 56 nondiabetic patients 56 mg kg belimumab 56 log# copies mL 56 PSA nadir 56 Hazard Ratio 56 octreotide LAR 56 achieved PASI 56 IIIa inhibitors 56 Kaplan Meier 56 femoral neck BMD 56 pCR 56 log# 56 Psoriasis Area 56 r = 56 #.#-#.# p = 56 HAQ DI 56 leuprorelin 56 NPH insulin 56 #mg/day [002] 56 severe exacerbations 56 mcg Albuferon 56 FOLPI 56 nonsignificant difference 56 preoperatively 56 sirolimus eluting stent 56 plus ribavirin 56 PASI scores 56 QRS duration 56 PANSS 56 plus GP IIb 56 Crohn Disease Activity 56 subscales 56 CCyR 56 HbA 1c 56 definite stent thrombosis 56 tipranavir r 56 mL/min/#.# m 2 56 ng mL 56 copies ml 56 pooled comparator 56 nmol liter 56 ABC/3TC 56 CrCl 56 posttransplant 56 mg qd 55 receiving VICTRELIS 55 Zometa hazard 55 PaO 2 55 Index CDAI 55 eptifibatide 55 virologic failure 55 plasma uric acid 55 etanercept 55 FluCAM 55 nicardipine 55 alanine aminotransferase 55 IFN α 55 -#.# log# copies mL 55 adefovir 55 HBeAg positive patients 55 events MACE 55 Cmax 55 bosentan 55 dapagliflozin plus 55 APTIVUS r 55 mmol l 55 partial remissions 55 serologically active patients 55 events AEs 55 HBeAg 55 PCa 55 serum phosphorus 55 CRp 55 Montgomery Asberg Depression 55 quetiapine 55 incontinence episodes 55 plus medroxyprogesterone acetate 55 statistically significant 55 Secondary efficacy endpoints 55 prior relapsers 55 radiotherapy RT 55 splenectomized 55 enoxaparin 55 pmol L 55 thromboembolic events 55 sinus rhythm 55 Q2W 55 LV ejection fraction 55 nodular partial response 55 IRLS 55 abdominal pain abdominal discomfort 55 HbA1C levels 55 UPDRS 55 mmHg 55 saline placebo 55 #mg BID [002] 55 nadolol 55 left ventricular systolic 55 adjunctive ABILIFY 55 baseline HbA1c 55 HBV DNA 55 recurrent venous thromboembolism 55 oxycodone IR 55 symptom severity 55 mg dose 55 irbesartan 55 infliximab monotherapy 55 systemic embolism 55 NIH CPSI 55 lymphopenia 55 CIMZIA TM certolizumab pegol 55 Partial Response 55 mg 55 LAB GHRH 55 5FU 55 spontaneous bowel movements 55 advanced adenoma 55 log# IU mL 55 oral allopurinol 55 mmHg diastolic 54 peginterferon alfa 2b 54 hours postdose 54 NATRECOR R 54 Viread Emtriva Sustiva 54 ribavirin RBV 54 liver histology 54 SBMs 54 insulin detemir 54 gout flares 54 locoregional recurrence 54 nonobese 54 HF hospitalization 54 highly emetogenic 54 % CI #.#-#.# [005] 54 virologic breakthrough 54 neutrophil counts 54 fatigue asthenia 54 recurrent VTE 54 reintervention 54 biphasic insulin aspart 54 CDAI score 54 secondary endpoints 54 g dL 54 unfractionated heparin 54 confidence intervals CIs 54 Thal Dex 54 nadroparin 54 mmol L 54 recurrent ischemia 54 plus prednisone 54 ACR# [002] 54 EDSS score 54 sumatriptan naproxen sodium 54 clopidogrel 54 thromboembolism 54 nonresponders 54 neointimal 54 IIIa inhibitor 54 mRS 54 CSBM 54 FOLFIRI 54 annualized relapse 54 Kaplan Meier curves 54 leukocyte count 54 tertile 54 receiving ISENTRESS 54 reach statistical significance 54 serum concentrations 54 mg tid 54 NIHSS 54 Visual Analogue Scale VAS 54 esomeprazole 54 lymph node metastasis 54 experienced virologic failure 54 TURBT 54 seminal vesicle invasion 54 PANSS total 54 REYATAZ r arm 54 abacavir lamivudine 54 intima media thickness 54 ALT normalization 54 clinically meaningful improvement 54 glimepiride 54 Adverse events 54 oblimersen 54 6MWD 54 ipsilateral 54 Primary endpoints 54 neutropaenia 54 plasma HCV RNA 54 8mg/kg 54 Postoperatively 54 DAPT 54 intramuscularly 54 dyspareunia 54 μg kg 54 rimonabant #mg 54 myocardial infarction MI 54 coronary revascularization 54 lumbar spine bone 54 solifenacin 54 IBDQ 54 perioperatively 54 primary patency 54 dexamethasone 54 IELT 54 placebo PBO 54 #mg/m# [001] 54 fasting plasma glucose FPG 54 neurologic progression 54 endoscopic remission 54 headache nasopharyngitis 54 mIU L 54 tapentadol ER 54 serum urate 54 Kaplan Meier estimates 54 plus glycoprotein IIb 54 REYATAZ r 54 hypophosphatemia 54 LV dysfunction 54 mcg linaclotide 54 placebo Hazard Ratio 54 Pain Intensity 54 serum HBV DNA 54 μg 54 paresthesias 54 alanine aminotransferase ALT 54 Visual Analog Scale 54 monotherapy 54 HAM D# 54 incidence ≥ 54 KRAS mutant tumors 54 mIU ml 54 pT3 54 XIENCE V vs. 54 colorectal adenoma 53 mcg albinterferon alfa 2b 53 alteplase 53 #μg [002] 53 doxorubicin docetaxel 53 NNT = 53 ezetimibe simvastatin 53 ng dl 53 myocardial infarction 53 postmenopausal osteoporotic women 53 diastolic BP 53 TMC# r 53 evaluable patients 53 comparator PI r 53 bupivacaine 53 ACTEMRA TM 53 tipranavir ritonavir 53 TDF FTC 53 hypomagnesemia 53 ATV RTV 53 infarct size 53 response CCyR 53 Expanded Disability Status 53 HOMA IR 53 albumin excretion rate 53 DAS# remission 53 VcMP 53 segment binary restenosis 53 salmeterol fluticasone propionate 53 conjunctival hyperemia 53 macroalbuminuria 53 FEV1 53 distant metastasis 53 TEAEs 53 pioglitazone 53 Disease Activity 53 nasopharyngitis headache 53 tertiles 53 IFN alfa 53 nasal symptom 53 flutamide 53 ritonavir boosted 53 #.#/#.# mm Hg [003] 53 ug kg 53 mg Androxal 53 -#.# log# 53 undetectable HCV RNA 53 pulmonary vascular 53 contralateral 53 urinary N telopeptide 53 atheroma volume 53 platelet reactivity 53 â ‰ ¥ 53 serum testosterone 53 -#.# ± [001] 53 erythrocyte sedimentation rate 53 mL sec 53 min -1 53 primary efficacy endpoint 53 DAS# scores 53 non splenectomized 53 methacholine challenge 53 p = ns 53 sUA levels 53 death reinfarction 53 eplerenone 53 interferon alfa 53 phonophobia 53 FluCAM arm 53 Brief Psychiatric 53 mg/m2 dose 53 hypoglycemic events 53 XIENCE V demonstrated 53 fluticasone salmeterol 53 Lucentis monotherapy 53 TPV r 53 BEACOPP 53 histologic 53 leucopenia 53 mg p = 53 hypokalemia 53 mEq L 53 PSADT 53 ketorolac 53 achieved CCyR 53 BARACLUDE ® 53 serum potassium 53 anemia hemoglobin 53 detrusor 53 VELCADE melphalan 53 Scale EDSS 53 XELOX 53 interferon alfa 2a 53 fraction LVEF 53 fluorouracil 53 Thrombolysis 53 F FDG PET 53 stage IIIb IV 53 ng ml 53 extrapyramidal symptoms 53 locoregional 53 endometrial thickness 53 intermittent dosing 53 IQR 53 PEG IFN 53 QD dosing 53 EDSS scores 53 postprocedure 53 Baseline characteristics 53 quetiapine XR 53 cytogenetic response 53 lamivudine 53 CsA 53 morphometric vertebral fractures 53 Apidra ® 53 doxazosin 53 mg + GLY 53 plus OBT 53 adalimumab 53 nausea photophobia 53 mg simvastatin 53 hemoglobin A1c levels 53 BMI z 53 CC genotype 53 beclomethasone dipropionate 53 patients evaluable 53 #ug [001] 53 amoxicillin clavulanate 53 neutrophil count 53 nmol L 53 fibrinolysis 53 piperacillin tazobactam 53 logMAR 53 aspartate aminotransferase 53 detrusor overactivity 53 T2 lesion volume 53 sUA 53 WOMAC 52 ACR# response 52 SCr 52 androgen suppression 52 insulin glargine 52 MMSE score 52 g dl 52 tenecteplase 52 uM 52 lymphadenectomy 52 radical prostatectomy RP 52 dalteparin 52 reoperation 52 linaclotide treated 52 metoprolol tartrate 52 abciximab 52 active comparator 52 log# reduction 52 myocardial infarction stroke 52 virological response 52 racemic albuterol 52 DAS# CRP 52 secondary efficacy endpoint 52 Negative Syndrome 52 Operative mortality 52 HBeAg positive 52 postoperative AF 52 Score DAS# 52 Erythropoietic therapies may 52 lamivudine monotherapy 52 creatinine clearance 52 SVR# 52 elevated transaminases 52 HAM D# scores 52 MetS 52 lymphocytosis 52 vertebral fracture 52 alfa 2a 52 CK # plasma concentrations 52 IM progesterone 52 renal insufficiency 52 LANTUS R 52 esophageal carcinoma 52 perioperative complications 52 Folfox 52 prospectively defined 52 subscale scores 52 intratumoral 52 TT genotype 52 fractional shortening 52 BARACLUDE r 52 pruritus 52 recurrent atrial fibrillation 52 CK MB 52 pericardial effusion 52 HBeAg negative 52 left ventricular LV 52 gadolinium enhancing 52 Key secondary endpoints 52 dysuria 52 preoperative chemotherapy 52 multivariate Cox 52 mg subcutaneously 52 cisplatin vinorelbine 52 HRQoL 52 OAB symptoms 52 Partial Responses 52 univariate analyzes 52 microbiological eradication 52 noninferior 52 Major Adverse Cardiac 52 coadministration 52 elevated ALT 52 #mg doses [002] 52 tumor histology 52 aPTT 52 ALND 52 dose dependently 52 DMARD 52 budesonide pMDI 52 Acetate Rectal Suppositories 52 QTc 52 univariate 52 trastuzumab 52 #.#ng/ml 52 serum cortisol 52 prespecified secondary 52 prostate cancer CaP 52 posaconazole 52 urinary albumin 52 sirolimus stent 52 analgesia 52 mild renal impairment 52 cytogenetic abnormalities 52 poststroke 52 imatinib 52 postoperative complication 52 olanzapine 52 bivalirudin monotherapy 52 nonvertebral 52 fondaparinux 52 CIMZIA ™ 52 femoral neck 52 deep venous thromboses 52 nmol 52 systolic function 52 umol L 52 nM 52 ALT elevation 52 mcg doses 52 ATACAND 52 mitoxantrone plus 52 revascularization 52 echocardiographic parameters 52 concomitant medications 52 LEXIVA 52 Taxus Stent 52 hemodynamically significant 52 sirolimus eluting stents 52 lamivudine refractory patients 52 IRLS score 52 dobutamine 52 mmHg systolic 52 Peg IFN 52 lactate dehydrogenase 52 chemoradiotherapy 52 Unified Parkinson Disease 52 cEVR 52 lymphocyte count 52 -#.# p = 52 upper gastrointestinal bleeding 52 ertapenem 52 Doxil ® 52 adenoma recurrence 52 ALVESCO 52 HCV genotype 1 52 advanced adenomas 52 rebleeding 52 CRu 52 bronchodilation 52 hsCRP levels 52 plasma glucose 52 NSTEMI 52 hemorrhagic complications 52 low dose Iluvien 52 pretreatment baseline 52 erythema 52 subcutaneous enoxaparin 52 demonstrated clinically meaningful 52 zoledronic acid 52 oral diclofenac 52 serum prostate 52 mL/min/#.# m2 52 noncarriers 52 adefovir treated 52 ritonavir boosted atazanavir 52 diastolic hypertension 52 -#.# mm Hg 52 extrapyramidal disorder 52 treatment emergent adverse 52 PCWP 52 EBMT criteria 52 progesterone receptor negative 52 rizatriptan 52 pegylated liposomal doxorubicin 52 revascularizations 52 achieved sustained virological 52 otamixaban 52 β blockers 52 bortezomib refractory 52 splenectomized patients 52 NYHA class 52 prespecified 52 asthenia 52 mTSS 52 distant metastases 52 prednisone prednisolone plus 51 tapentadol IR 51 vasomotor 51 WOMAC scores 51 adriamycin 51 iodixanol 51 hematologic toxicity 51 mesalamine granules 51 pulmonary exacerbation 51 seropositive patients 51 gastric pH 51 df = 51 Score TOS 51 dexmedetomidine 51 apnea hypopnea index 51 Cypher Stent 51 mcg 51 salivary cortisol 51 low dose cytarabine 51 Preoperatively 51 detectable HCV RNA 51 ARCOXIA 51 rCBF 51 valsartan 51 stomatitis 51 nighttime awakenings 51 glycosylated hemoglobin HbA1c 51 relapsed MM 51 #q# deletion syndrome 51 multivariable analysis 51 GnRH agonist 51 Y BOCS 51 valacyclovir 51 IU ml 51 Global Impression 51 kg -1 51 thrombocytopenia 51 mcg dose 51 Kaplan Meier estimate 51 mg/m2 51 intact parathyroid hormone 51 HIV uninfected 51 HbA1c 51 arterial thromboembolic events 51 nonmetastatic 51 radiographic progression 51 sensory neuropathy 51 bivalirudin 51 divalproex 51 evaluable subjects 51 % CI #.#-#.# [004] 51 nonfatal stroke 51 undetectable HBV DNA 51 oral rivaroxaban 51 low dose dexamethasone 51 estimated glomerular filtration 51 elevated troponin 51 lymphovascular invasion 51 AOR = 51 Hb A1C 51 fibrinolytic therapy 51 malignancy HCM 51 hepatic metastases 51 PREZISTA r 51 cerebrovascular accident 51 Lupuzor ™ 51 baseline A1C 51 ramipril 51 GOUT 51 colorectal carcinoma 51 PRADAXA #mg 51 primary percutaneous coronary 51 decitabine 51 transaminases 51 RECIST criteria 51 Durezol 51 cytogenic 51 complete cytogenetic 51 olmesartan 51 ULORIC 51 telaprevir dosed 51 LVSD 51 postoperative morbidity 51 lactate dehydrogenase LDH 51 lamotrigine 51 MMSE scores 51 symptomatic VTE 51 Index CDAI score 51 HAMD 51 idraparinux 51 plasma glucose levels 51 sustained virologic response 51 fluoxetine 51 trough FEV1 51 GP IIb IIIa 51 pharmacokinetics PK 51 rosuvastatin #mg 51 #.#/#.# mm Hg [001] 51 chemoradiation therapy 51 mutated KRAS 51 hypogonadal men 51 pmol liter 51 ventricular tachyarrhythmia 51 tibiofemoral 51 retropubic 51 TIMP 1 51 carboplatin paclitaxel 51 antibody titer 51 aspartate aminotransferase AST 51 Navelbine 51 elevated IOP 51 Kaplan Meier survival 51 DOXIL 51 dyspnoea 51 mg m² 51 glycosylated hemoglobin levels 51 ml kg 51 Pharmacokinetics PK 51 aromatase inhibitor therapy 51 microg 51 overt nephropathy 51 aOR 51 urine albumin 51 partial thromboplastin 51 AUA Symptom Score 51 administered subcutaneously 51 paclitaxel eluting stents 51 serum IGF 51 Timed Walk 51 serum PTH 51 mRNA expression 51 crossclamp 51 mg hydrochlorothiazide 51 docetaxel prednisone 51 nondepressed 51 hypogonadal 51 arthralgia 51 inadequate glycemic 51 corrected QT interval 51 salmeterol fluticasone 51 seroconversion 51 oral antidiabetic medication 51 Fasting plasma glucose 51 locoregional control 51 moderate renal impairment 51 peginterferon 51 lispro alone 51 VIRAMUNE 51 serum aminotransferase levels 51 Rating Scale BPRS 51 docetaxel 51 budesonide formoterol 51 MBq 51 KRAS mutations occur 51 euthyroid 51 nucleoside naive 51 pamidronate 51 thromboembolic 51 #mg/dL [002] 51 ≤ 51 ischemic lesions 51 affective psychosis 51 rs# [003] 51 FLT3 ITD 51 acute coronary syndromes ACS 51 idarubicin 51 AGILECT R 51 receiving prophylactic anticoagulation 51 VT VF 51 left ventricular dysfunction 51 NYHA functional class 51 serum phosphorous 51 repeat revascularization 51 genotypic resistance 51 intraoperative 51 unresectable HCC 51 antibody titers 51 variceal bleeding 51 zolmitriptan 51 glycosylated hemoglobin 51 alfuzosin 51 #mg dose [003] 51 biopsy Gleason 51 receiving highly emetogenic 51 mRCC 51 aminotransferase elevations greater 51 antiretroviral naïve 51 unfractionated heparin UFH 51 gadolinium enhancing lesions 51 glycoprotein IIb IIIa inhibitor 51 ADAS Cog 51 hyperacute 51 neostigmine 51 complete cytogenetic response 51 statistical significance p 51 proteinuria 51 ejection fraction EF 51 Score IPSS 51 CFQ R 51 ACTH 51 mediastinal 51 ziprasidone 51 Engerix B 51 isoproterenol 51 atorvastatin #mg 50 peginterferon alfa 2a #KD 50 mg doses 50 asthenia fatigue 50 Hb 50 response pCR 50 CABG 50 multivariate analysis 50 uncoated stent 50 linezolid 50 stent thromboses 50 Fludara 50 mL min 50 Perforomist Inhalation Solution 50 rFSH 50 SBM frequency 50 symptomatic AF 50 specific antigen PSA 50 cystectomy 50 cells mcL 50 hepatic enzymes 50 PREZISTA r arm 50 proximal DVT 50 cells uL 50 glycated hemoglobin levels 50 CSBMs 50 ABCB1 50 mg clopidogrel 50 secondary efficacy endpoints 50 paricalcitol 50 multivariate adjustment